studies with efficacy and safety outcomes with relevant interventions in patients with stage I-III MCC. The review included monotherapies or combinations of pharmacological treatments, radiotherapy (RT), chemotherapy (CT), and surgery (SUR). Adjuvant (adj
Search Results
CLO21-022: Efficacy and Safety Outcomes With Therapies for Stage I-III Merkel Cell Carcinoma (MCC): A Systematic Literature Review
David Miller, Roberto Palencia, Ting Yu, Amrita Sandhu, Sarah Webb, Tom Blaikie, and Murtuza Bharmal
HSR21-067: What Patient-Reported Outcomes Are Being Used in Non-small Cell Lung Cancer? A Targeted Literature Review of Randomized Clinical Trials and Regulatory Labeling
Kajal Patel, Soham Shukla, Jennifer Hanlon, Kelly Bell, Laurie Eliason, and Cosmina Hogea
-reported outcome (PRO) data, an important resource in the field of oncology, has the potential to offer direct insight into the patient’s treatment experience, beyond efficacy and safety measures. Methods: A targeted literature search for PROs was performed using
HSR20-108: Treatment Patterns and Outcomes in US Adults with Metastatic Non-Small Cell Lung Cancer: A Retrospective Cohort Study of First-Line Treatments
Ashley Tabah, David Huggar, Ronda Copher, Marc Tian, and Ali McBride
real-world treatment patterns and outcomes in metastatic NSCLC patients treated with a first line (1L) therapy. Methods: A retrospective cohort analysis of IBM MarketScan@ Commercial and Medicare Supplemental Claims Databases was conducted. The
HSR20-105: The Impact of Gastric Cancer Clinical Pathways Based on National Comprehensive Cancer Network Guidelines on Treatment Heterogeneity and Clinical Outcomes in the US Oncology Network
Scott Paulson, Curtis Waycaster, Bismark Baidoo, Astra M. Liepa, Anindya Chatterjee, and Lisa M. Hess
Background: It is generally assumed that adherence to clinical practice guidelines can reduce treatment variability and improve patient outcomes. Gastric cancer clinical treatment pathways were implemented in the US Oncology Network (USON) in
BBCIC Research Network Analysis of First-Cycle Prophylactic G-CSF Use in Patients Treated With High–Neutropenia Risk Chemotherapy
Pamala A. Pawloski, Cara L. McDermott, James H. Marshall, Vanita Pindolia, Catherine M. Lockhart, Catherine A. Panozzo, Jeffrey S. Brown, and Bernadette Eichelberger
use in real-world settings are maturing, and critical pharmacovigilance of these products depends on the understanding of their use and clinical impact. 30 , 31 Similar clinical and safety outcomes of the G-CSF biosimilars compared with their
Does Adjuvant Bisphosphonate in Early Breast Cancer Modify the Natural Course of the Disease? A Meta-Analysis of Randomized Controlled Trials
Davide Mauri, Antonis Valachis, Nikolaos P. Polyzos, Lamprini Tsali, Dimitris Mavroudis, Vassilis Georgoulias, and Giovanni Casazza
-analysis calculations. Data Extraction and Outcomes Information recorded from each eligible trial included author names; journal; year of publication; number of centers involved; number of patients randomly assigned and analyzed per arm; years of patient
BIO22-031: Potential Implications in Immunotherapy and Prognostic Outcomes of Non-Small Cell Lung Cancer for Computational Recognition of lncRNA Signature of Tumor-Associated Neutrophils
Zhuoran Tang, Chunyu Li, Peixin Chen, Haoyue Guo, Jinpeng Shi, Yingying Pan, Qi Wang, and Caicun Zhou
characteristics. The risk score was determined using LASSO Cox regression analysis. Meanwhile, we named this risk score as “TANlncSig”. TANlncSig was able to distinguish between better and worse survival outcomes in various patient datasets independently of other
Effect of Hepatitis C Virus Infection in Patients With Cancer: Addressing a Neglected Population
Harrys A. Torres, Parag Mahale, Boris Blechacz, Ethan Miller, Ahmed Kaseb, H. Franklin Herlong, Nathan Fowler, Ying Jiang, Issam I. Raad, and Dimitrios P. Kontoyiannis
natural history, management, and outcome. Professional societies have published guidelines for the diagnosis, management, and treatment of HCV infection, 9 specific sections of which address immunocompromised patients, such as HIV coinfected patients and
HSR23-120: Real-World Observations Show Beneficial Outcomes in Patients With NSCLC Treated With Pembrolizumab for More Than 2 Years
Lucio Gordan, Rushir Choksi, Daniel Petro, Melissa Johnson, Anupama Vasudevan, Sandy English, Marielle Fares, Heidi Gidley, Teena Sura, and Prateesh Varughese
at patient outcomes after >2 years of P treatment. The aim of this real-world study was to evaluate patient outcomes related to P use for >2 years in patients with stage IV NSCLC. Using the de-identified Precision Q database, authors evaluated
CLO23-057: The Influence of Operability Status on Outcomes in Patients With T4a Larynx Cancer: An Institutional Experience
Ashley Schlafstein, Subir Goyal, Ashley Aiken, Jill Remick, Nabil Saba, James Bates, Soumon Rudra, Mark McDonald, Azeem Kaka, and William Stokes
Purpose/Objective(s): Analyses of national care patterns and outcomes among patients with T4 laryngeal squamous cell carcinoma (L-SCC) have demonstrated a concomitant increase in the use of larynx preservation (LP) and a decrease in overall
